Relation of Asymmetric Dimethylarginine Levels to Macrovascular Disease and Inflammation Markers in Type 2 Diabetic Patients

Table 1

Comparison of the common parameters in MVD, non-MVD, and the control group.

	MVD (a)	non-MVD (b)	Control (c)
Age (years)	61.86 ± 7.96	56.8 ± 8.94	55.06 ± 7.46	(a-c) 𝑃<0.001, (a-b) 𝑃<0.01
BMI (kg/m^2)	29.59 ± 4.76	30.44 ± 6.22	27.83 ± 2.68	𝑃>0.05
SBP (mm/Hg)	126.20 ± 13.07	125.40 ± 15.31	121.77 ± 9.53	𝑃>0.05
DBP (mm/Hg)	80.80 ± 8.16	77.90 ± 12.86	80.80 ± 8.76	𝑃>0.05
D. of diabetes (Years)	12.98 ± 7.24	9.08 ± 5.75		𝑃<0.01
HbA1c (%)	9.41 ± 2.63	9.88 ± 2.93		𝑃>0.05
CCr (mL/min)	84.25 ± 40.55	95.27 ± 42.38		𝑃>0.05
Albuminuria (mg/day)	305.20 ± 946.28	110.70 ± 238.78		𝑃>0.05
C-Peptide (ng/mL)	2.21 ± 1.77	2.17 ± 1.23		𝑃>0.05
PBG (mg/dL)	171.56 ± 76.20	202.72 ± 99.52	86.87 ± 8.65	(b-c) 𝑃<0.05, (a-c) 𝑃<0.05
Creatinine (mg/dL)	1.01 ± 0.25	0.85 ± 0.18	0.82 ± 0.15	(a-b) 𝑃<0.05, (a-c) 𝑃<0.05
Triglyceride (mg/dL)	188.68 ± 109.11	185.44 ± 101.35	141.19 ± 78.74	(a-c) 𝑃<0.05, (b-c) 𝑃<0.05
HDL (mg/dL)	50.80 ± 13.95	49.74 ± 10.31	54.20 ± 13.18	𝑃>0.05
T. cholesterol (mg/dL)	181.26 ± 46.90	189.16 ± 43.81	203.38 ± 33.94	𝑃>0.05
LDL (mg/dL)	113.40 ± 36.89	121.50 ± 34.24	137.58 ± 32.56	(c-a) 𝑃<0.01, (c-b) 𝑃<0.05
Sedimentation (mm/hr)	25.38 ± 21.88	18.60 ± 15.35	12.51 ± 8.31	(a-c) 𝑃<0.05
CRP (mg/L)	7.71 ± 9.21	6.57 ± 11.42	2.36 ± 1.85	(a-c) 𝑃<0.05
Fibrinogen (mg/dL)	386.66 ± 91.74	370.32 ± 68.31	344.51 ± 55.69	(a-c) 𝑃<0.05
Homocysteine (umol/L)	11.78 ± 3.85	11.38 ± 3.86	10.58 ± 3.59	𝑃>0.05
B12 (pg/mL)	537.84 ± 381.73	449.14 ± 309.35	421.03 ± 274.66	𝑃>0.05
Folic acid (ng/mL)	9.27 ± 3.57	9.51 ± 3.58	9.93 ± 8.14	𝑃>0.05
Car.Int-R (mm)	0.96 ± 0.23	0.89 ± 0.24	0.78 ± 0.19	(a-c) 𝑃<0.05
Car.Int-L (mm)	0.93 ± 0.18	0.93 ± 0.28	0.79 ± 0.19	(a-c) 𝑃<0.05, (b-c) 𝑃<0.05
ADMA (umol/L)	0.52 ± 0.23	0.39 ± 0.16	0.32 ± 0.13	(a-b) 𝑃<0.05, (a-c) 𝑃<0.05

BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; D. of diabetes: duration of diabetes.